As of 2025-07-11, the EV/EBITDA ratio of Inovio Pharmaceuticals Inc (INO) is -0.44. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. INO's latest enterprise value is 45.75 mil USD. INO's TTM EBITDA according to its financial statements is -105.00 mil USD. Dividing these 2 quantities gives us the above INO EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.8x - 17.2x | 14.3x |
| Forward P/E multiples | 26.4x - 34.8x | 31.0x |
| Fair Price | (44.33) - (28.72) | (37.90) |
| Upside | -3289.2% - -2166.5% | -2826.5% |
| Date | EV/EBITDA |
| 2025-07-10 | -0.44 |
| 2025-07-09 | -0.47 |
| 2025-07-08 | -0.41 |
| 2025-07-07 | -0.40 |
| 2025-07-03 | -0.40 |
| 2025-07-02 | -0.88 |
| 2025-07-01 | -0.82 |
| 2025-06-30 | -0.81 |
| 2025-06-27 | -0.86 |
| 2025-06-26 | -0.94 |
| 2025-06-25 | -0.92 |
| 2025-06-24 | -0.83 |
| 2025-06-23 | -0.75 |
| 2025-06-20 | -0.77 |
| 2025-06-18 | -0.76 |
| 2025-06-17 | -0.74 |
| 2025-06-16 | -0.79 |
| 2025-06-13 | -0.79 |
| 2025-06-12 | -0.84 |
| 2025-06-11 | -0.86 |
| 2025-06-10 | -0.94 |
| 2025-06-09 | -0.92 |
| 2025-06-06 | -0.95 |
| 2025-06-05 | -0.86 |
| 2025-06-04 | -0.89 |
| 2025-06-03 | -0.86 |
| 2025-06-02 | -0.85 |
| 2025-05-30 | -0.79 |
| 2025-05-29 | -0.87 |
| 2025-05-28 | -0.79 |
| 2025-05-27 | -0.79 |
| 2025-05-23 | -0.78 |
| 2025-05-22 | -0.81 |
| 2025-05-21 | -0.78 |
| 2025-05-20 | -0.87 |
| 2025-05-19 | -0.83 |
| 2025-05-16 | -0.82 |
| 2025-05-15 | -0.76 |
| 2025-05-14 | -0.72 |
| 2025-05-13 | -0.75 |
| 2025-05-12 | -0.76 |
| 2025-05-09 | -0.68 |
| 2025-05-08 | -0.69 |
| 2025-05-07 | -0.65 |
| 2025-05-06 | -0.62 |
| 2025-05-05 | -0.71 |
| 2025-05-02 | -0.75 |
| 2025-05-01 | -0.73 |
| 2025-04-30 | -0.76 |
| 2025-04-29 | -0.74 |